Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels

ABSTRACT Background Current approach to clinically suspicious biopsy‐naïve men consists performing prostate MRI, followed by combined systematic (TRUS‐Bx) and MRI‐Ultrasound fusion biopsy (MRI‐TBx) in those with PIRADS score ≥ 3. Researchers have attempted to determine who benefits from each biopsy...

Full description

Saved in:
Bibliographic Details
Main Authors: Solmaz Ohadian Moghadam, Mohammad Haddadi, Erfan Amini, Seyed Ali Momeni, Masoud Bitaraf, Mohammad Reza Nowroozi
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Reports
Subjects:
Online Access:https://doi.org/10.1002/cnr2.70099
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832577736809381888
author Solmaz Ohadian Moghadam
Mohammad Haddadi
Erfan Amini
Seyed Ali Momeni
Masoud Bitaraf
Mohammad Reza Nowroozi
author_facet Solmaz Ohadian Moghadam
Mohammad Haddadi
Erfan Amini
Seyed Ali Momeni
Masoud Bitaraf
Mohammad Reza Nowroozi
author_sort Solmaz Ohadian Moghadam
collection DOAJ
description ABSTRACT Background Current approach to clinically suspicious biopsy‐naïve men consists performing prostate MRI, followed by combined systematic (TRUS‐Bx) and MRI‐Ultrasound fusion biopsy (MRI‐TBx) in those with PIRADS score ≥ 3. Researchers have attempted to determine who benefits from each biopsy method, but the results do not support the safe use of one method alone. This study aims to determine the optimal approach in biopsy‐naïve men, according to their PSA levels. Methods and Results A retrospective chart review of clinically suspicious biopsy‐naïve men who underwent both TRUS‐Bx and MRI‐TBx was done. Prostate specific antigen (PSA) levels were compared between patients only positive for MRI‐TBx and those with positive TRUS‐Bx. Further, cancer cases were divided to < 10 and ≥ 10 PSA groups and the pathology results, obtained by each method, were compared. Out of 195 men, 36 were diagnosed with prostate cancer (PCa). PCa was diagnosed by both MRI‐TBx and TRUS‐Bx in 26 men, half of whom had PSA > 10 ng/mL. At PSA ≤ 10 ng/mL, PCa would have been missed in 4 men (11.1%) had MRI‐TBx not been done, and in 6 men (16.6%) had TRUS‐Bx not been done. Conclusion Despite attempts to perform only one biopsy method in men with clinical suspicion of prostate cancer, we propose that at least in men with PSA ≤ 10 ng/mL, both systematic and MRI‐targeted biopsies be performed.
format Article
id doaj-art-4699519c46bb4935b5dcf015c8451cfb
institution Kabale University
issn 2573-8348
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Cancer Reports
spelling doaj-art-4699519c46bb4935b5dcf015c8451cfb2025-01-30T15:46:35ZengWileyCancer Reports2573-83482025-01-0181n/an/a10.1002/cnr2.70099Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) LevelsSolmaz Ohadian Moghadam0Mohammad Haddadi1Erfan Amini2Seyed Ali Momeni3Masoud Bitaraf4Mohammad Reza Nowroozi5Uro‐Oncology Research Center Tehran University of Medical Sciences Tehran IranUro‐Oncology Research Center Tehran University of Medical Sciences Tehran IranUro‐Oncology Research Center Tehran University of Medical Sciences Tehran IranUro‐Oncology Research Center Tehran University of Medical Sciences Tehran IranUro‐Oncology Research Center Tehran University of Medical Sciences Tehran IranUro‐Oncology Research Center Tehran University of Medical Sciences Tehran IranABSTRACT Background Current approach to clinically suspicious biopsy‐naïve men consists performing prostate MRI, followed by combined systematic (TRUS‐Bx) and MRI‐Ultrasound fusion biopsy (MRI‐TBx) in those with PIRADS score ≥ 3. Researchers have attempted to determine who benefits from each biopsy method, but the results do not support the safe use of one method alone. This study aims to determine the optimal approach in biopsy‐naïve men, according to their PSA levels. Methods and Results A retrospective chart review of clinically suspicious biopsy‐naïve men who underwent both TRUS‐Bx and MRI‐TBx was done. Prostate specific antigen (PSA) levels were compared between patients only positive for MRI‐TBx and those with positive TRUS‐Bx. Further, cancer cases were divided to < 10 and ≥ 10 PSA groups and the pathology results, obtained by each method, were compared. Out of 195 men, 36 were diagnosed with prostate cancer (PCa). PCa was diagnosed by both MRI‐TBx and TRUS‐Bx in 26 men, half of whom had PSA > 10 ng/mL. At PSA ≤ 10 ng/mL, PCa would have been missed in 4 men (11.1%) had MRI‐TBx not been done, and in 6 men (16.6%) had TRUS‐Bx not been done. Conclusion Despite attempts to perform only one biopsy method in men with clinical suspicion of prostate cancer, we propose that at least in men with PSA ≤ 10 ng/mL, both systematic and MRI‐targeted biopsies be performed.https://doi.org/10.1002/cnr2.70099fusion biopsyMRI‐targeted biopsyprostate cancerprostate specific antigenPSAtransrectal biopsy
spellingShingle Solmaz Ohadian Moghadam
Mohammad Haddadi
Erfan Amini
Seyed Ali Momeni
Masoud Bitaraf
Mohammad Reza Nowroozi
Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
Cancer Reports
fusion biopsy
MRI‐targeted biopsy
prostate cancer
prostate specific antigen
PSA
transrectal biopsy
title Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
title_full Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
title_fullStr Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
title_full_unstemmed Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
title_short Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
title_sort value of systematic and mri ultrasound fusion prostate biopsy in different prostate specific antigen psa levels
topic fusion biopsy
MRI‐targeted biopsy
prostate cancer
prostate specific antigen
PSA
transrectal biopsy
url https://doi.org/10.1002/cnr2.70099
work_keys_str_mv AT solmazohadianmoghadam valueofsystematicandmriultrasoundfusionprostatebiopsyindifferentprostatespecificantigenpsalevels
AT mohammadhaddadi valueofsystematicandmriultrasoundfusionprostatebiopsyindifferentprostatespecificantigenpsalevels
AT erfanamini valueofsystematicandmriultrasoundfusionprostatebiopsyindifferentprostatespecificantigenpsalevels
AT seyedalimomeni valueofsystematicandmriultrasoundfusionprostatebiopsyindifferentprostatespecificantigenpsalevels
AT masoudbitaraf valueofsystematicandmriultrasoundfusionprostatebiopsyindifferentprostatespecificantigenpsalevels
AT mohammadrezanowroozi valueofsystematicandmriultrasoundfusionprostatebiopsyindifferentprostatespecificantigenpsalevels